Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
Evotec SE has announced the sale of its chemical API manufacturing site, Evotec DS GmbH in Halle/Westphalia, to Monacum Partners GmbH. The divestment is part of Evotec's 'Priority Reset' initiative launched in April 2024, aimed at fostering profitable growth through operational refinement. The facility, which specializes in chemical APIs, intermediates, and building blocks manufacturing, will continue operations under the new name DAPIN GmbH. The entire workforce will transition to the new ownership, with Monacum Partners committed to maintaining and growing the business. Financial details were not disclosed.
Evotec SE ha annunciato la vendita del suo stabilimento di produzione di API chimici, Evotec DS GmbH a Halle/Westfalia, a Monacum Partners GmbH. La dismissione fa parte dell'iniziativa 'Priority Reset' avviata da Evotec nell'aprile 2024, mirata a favorire una crescita proficua attraverso un affinamento operativo. Lo stabilimento, specializzato nella produzione di API chimici, intermedi e blocchi fondamentali, continuerà le sue attività sotto il nuovo nome DAPIN GmbH. L'intero personale passerà alla nuova proprietà, con Monacum Partners impegnata a mantenere e far crescere l'attività. I dettagli finanziari non sono stati divulgati.
Evotec SE ha anunciado la venta de su planta de fabricación de API químicos, Evotec DS GmbH en Halle/Westfalia, a Monacum Partners GmbH. La desinversión es parte de la iniciativa 'Priority Reset' lanzada por Evotec en abril de 2024, con el objetivo de fomentar un crecimiento rentable mediante la refinación operativa. La instalación, que se especializa en la producción de API químicos, intermedios y bloques de construcción, continuará sus operaciones bajo el nuevo nombre DAPIN GmbH. Toda la fuerza laboral pasará a la nueva propiedad, con Monacum Partners comprometido a mantener y hacer crecer el negocio. No se divulgaron detalles financieros.
Evotec SE는 Evotec DS GmbH의 화학 API 제조 시설을 Monacum Partners GmbH에 판매했다고 발표했습니다. 이번 매각은 2024년 4월에 시작된 Evotec의 'Priority Reset' 이니셔티브의 일환으로, 운영 정제를 통해 수익성 있는 성장을 촉진하는 것을 목표로 하고 있습니다. 이 시설은 화학 API, 중간체 및 빌딩 블록 제조를 전문으로 하며, 새로운 이름인 DAPIN GmbH로 계속 운영될 것입니다. 전체 직원은 새로운 소유권으로 이전되며, Monacum Partners는 비즈니스를 유지하고 성장시키겠다는 의지를 보이고 있습니다. 재무 세부사항은 공개되지 않았습니다.
Evotec SE a annoncé la vente de son site de fabrication d'API chimiques, Evotec DS GmbH à Halle/Westphalie, à Monacum Partners GmbH. La cession fait partie de l'initiative 'Priority Reset' lancée par Evotec en avril 2024, visant à favoriser une croissance rentable grâce à un affinage opérationnel. L'installation, qui se spécialise dans la fabrication d'API chimiques, d'intermédiaires et de blocs de construction, poursuivra ses activités sous le nouveau nom DAPIN GmbH. L'ensemble du personnel sera transféré à la nouvelle propriété, avec Monacum Partners engagé à maintenir et à développer l'activité. Les détails financiers n'ont pas été divulgués.
Evotec SE hat den Verkauf ihres chemischen API-Produktionsstandorts, Evotec DS GmbH in Halle/Westfalen, an Monacum Partners GmbH bekannt gegeben. Die Veräußertung ist Teil der von Evotec im April 2024 gestarteten Initiative 'Priority Reset', die darauf abzielt, profitables Wachstum durch betriebliche Verfeinerung zu fördern. Die Einrichtung, die sich auf die Herstellung von chemischen APIs, Zwischenprodukten und Bausteinen spezialisiert hat, wird unter dem neuen Namen DAPIN GmbH weiter betrieben. Die gesamte Belegschaft wird an die neue Eigentümerschaft überführt, wobei Monacum Partners sich verpflichtet hat, das Geschäft aufrechtzuerhalten und auszubauen. Finanzielle Einzelheiten wurden nicht bekanntgegeben.
- Strategic alignment with company's operational optimization efforts
- Focus on core growth drivers and competencies
- Reduction in manufacturing capabilities through facility divestment
- Loss of revenue stream from API manufacturing operations
Insights
The divestment of Evotec DS aligns with the company's "Priority Reset" strategic initiative, signaling a deliberate shift to streamline operations and focus on core growth areas. While financial terms remain undisclosed, this move should improve operational efficiency and resource allocation. The transaction transfers all operations and staff to Monacum Partners, minimizing potential restructuring costs and maintaining business continuity.
The strategic realignment could positively impact Evotec's margins and capital efficiency by removing a non-core asset from its portfolio. The CDMO market faces intense competition and this divestment allows Evotec to concentrate resources on higher-margin, technology-driven segments. The deal structure, preserving workforce and operations, suggests a clean exit that should minimize disruption to ongoing business relationships.
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners
Transaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth drivers
New ownership committed to maintaining and growing the business
HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm. This transaction forms part of Evotec's "Priority Reset" initiative launched in April 2024, which aims to foster profitable growth by refining the company's operational footprint and focusing on its primary growth sectors and core competencies.
Evotec DS in Halle/Westphalia is a specialized CDMO (Contract Development and Manufacturing Organization) with a strong foundation in chemical APIs, intermediates, and building blocks, which provides an end-to-end service portfolio, encompassing development to commercial-scale manufacturing.
The transaction presents an opportunity for Evotec DS to achieve its growth ambitions under new ownership. Under the agreement, all business operations and the entire workforce at Evotec DS will transition to Monacum Partners and continue business as DAPIN GmbH (Deutsche API & Intermediates). Financial terms of the transaction were not disclosed.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
About Monacum Partners
Monacum Partners is a Munich based private equity firm, focused on repositioning of European headquartered businesses. The core of Monacum Partners strategy, is acquiring underperforming companies with significant operational improvement potential and support them through proven turnaround playbooks, implemented by Monacum Partners' highly experienced operational team. For additional information please go to www.monacumpartners.com.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
Media
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
What is the purpose of Evotec's (EVO) sale of its Halle/Westphalia facility?
Who purchased Evotec's (EVO) API manufacturing facility?
What will happen to Evotec DS employees after the sale?
What is the new name of Evotec's former API facility?
